VR Logo

Unrated

Nippon India Pharma Fund - Direct Plan download report


1 Lakh

Investment Grown to
₹ 2.08 Lakh

₹ 10000

Monthly SIP Grown to
₹ 4.66 Lakh

Suitability:

This is a fund that invests mainly in shares of pharmaceutical and healthcare companies.

We believe that investors should avoid funds that have a narrowly defined investment mandate such as this one. Instead, they should invest in flexi-cap funds which provide complete freedom to the fund management team to invest in companies from which it expects maximum gains.

But if you do invest, you must do so only through the SIP route. Click here to read a primer on SIP investing.

Warning: Do not invest in this, or any other pharma sector fund, if you need to redeem your investment in less than seven years.

Taxability of earnings:

Capital gains

  • If the mutual fund units are sold after 1 year from the date of investment, gains upto Rs 1 lakh in a financial year are exempt from tax. Gains over Rs 1 lakh are taxed at the rate of 10%.
  • If the mutual fund units are sold within 1 year from the date of investment, entire amount of gain is taxed at the rate of 15%.
  • No tax is to be paid as long as you continue to hold the units.

Dividends

  • Dividends are added to the income of the investors and taxed according to their respective tax slabs. Further, if an investor's dividend income exceeds Rs. 5,000 in a financial year, the fund house also deducts a TDS of 10% before distributing the dividend.

Read more

ajax-loader
Please wait...

ajax-loader
Please wait...

(₹)
cal
cal

ajax-loader
Please wait...

Trailing Returns (%)

YTD 1-Day 1-W 1-M 3-M 6-M 1-Y 3-Y 5-Y 7-Y 10-Y
Nippon India Pharma Direct-G -10.18 -0.05 0.00 2.70 3.21 0.04 -8.53 27.73 19.28 10.32 --
S&P BSE Healthcare TRI -10.85 -0.21 -0.20 2.85 2.43 -2.14 -10.75 23.80 13.18 4.45 --
Equity: Sectoral-Pharma -9.74 -0.28 -0.51 1.92 3.13 -0.99 -8.56 26.77 16.15 7.82 --
Rank within category 7 1 2 2 6 1 5 4 1 1 --
Number of funds in category 10 10 10 10 10 10 9 9 4 3 0

As on 18-Aug-2022

Peer Comparison

Fund name Rating Launch Date 1-Year Return 3-Year Return 5-Year Return Expense Ratio Assets (Cr)
Nippon India Pharma Fund - Direct Plan
Unrated
Jan-13 -8.53 27.73 19.28 1.06 4,620
ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund - Direct Plan  | Invest Now
Unrated
Jul-18 -8.17 27.84 -- 1.22 2,503
Mirae Asset Healthcare Fund - Direct Plan  | Invest Online
Unrated
Jul-18 -6.00 31.89 -- 0.62 1,738
SBI Healthcare Opportunities Fund - Direct Plan  | Invest Online
Unrated
Jan-13 -6.27 26.88 13.66 1.07 1,668
DSP Healthcare Fund - Direct Plan
Unrated
Nov-18 -9.05 30.55 -- 0.81 1,196

Best & Worst Performance

Best Performance Worst Performance
Return (%) Period Return (%) Period
Week 21.40 01-Apr-2020 - 09-Apr-2020 -12.21 05-Mar-2020 - 12-Mar-2020
Month 38.63 23-Mar-2020 - 22-Apr-2020 -21.01 20-Feb-2020 - 23-Mar-2020
Quarter 47.66 23-Mar-2020 - 22-Jun-2020 -14.04 29-Dec-2015 - 29-Mar-2016
Year 90.70 23-Mar-2020 - 23-Mar-2021 -15.12 08-Sep-2016 - 08-Sep-2017

Risk Measures (%)

Mean Std Dev Sharpe Sortino Beta Alpha
Nippon India Pharma Direct-G 25.93 21.00 1.07 2.05 0.92 4.70
S&P BSE Healthcare TRI 22.78 22.44 0.86 1.63 -- --
Equity: Sectoral-Pharma 25.22 20.50 1.06 2.09 0.89 4.52
Rank within category 4 6 5 5 6 4
Number of funds in category 9 9 9 9 9 9

The Risk Measures have been calculated using calendar month returns for the last three years.

As on 31-Jul-2022

Asset Allocation (%)

ajax-loader
Please wait...

Concentration & Valuation

Number of Stocks 27
Top 10 Stocks (%) 70.26
Top 5 Stocks (%) 44.85
Top 3 Sectors (%) 99.34
Portfolio P/B Ratio 4.26
Portfolio P/E Ratio 29.75

Portfolio Aggregates

Fund Category
Average Mkt Cap (Rs Cr) 41,371 56,506
Giant (%) 15.01 20.17
Large (%) 32.90 35.87
Mid (%) 43.89 36.51
Small (%) 8.20 7.35
Tiny (%) -- 0.54

Value Research Fund Style

Sector Allocation vis-à-vis Category

ajax-loader
Please wait...

Top Holdings

Company Sector P/E 3Y High 3Y Low % Assets
equal Sun Pharmaceutical Industries Healthcare 56.51 14.91 9.05 14.91
equal Cipla Healthcare 33.50 10.40 6.69 8.46
up Dr. Reddy's Lab Healthcare 23.51 11.04 6.99 7.53
equal Divi's Laboratories Healthcare 32.01 10.71 6.89 7.47
up Torrent Pharmaceuticals Healthcare 66.12 6.87 0.00 6.48
equal Lupin Healthcare -- 10.30 4.76 6.00
down Narayana Hrudayalaya Healthcare 39.08 6.59 1.49 5.75
down Abbott India Healthcare 49.96 7.97 2.23 5.60
equal Aurobindo Pharma Healthcare 14.24 11.96 4.08 4.14
down Fortis Healthcare Healthcare 52.97 7.28 3.28 3.92
equal JB Chemicals & Pharma Healthcare 37.49 3.24 0.00 3.24
down Sanofi India Healthcare 15.00 5.82 1.86 3.05
up Gland Pharma Healthcare 36.23 6.63 0.00 2.94
equal Apollo Hospitals Healthcare 69.51 6.76 0.00 2.74
equal Thyrocare Technologies Healthcare 24.25 6.84 2.44 2.44
equal Pfizer Healthcare 43.32 2.56 0.00 2.43
equal Alkem Laboratories Healthcare 26.84 6.36 0.04 1.97
down Zydus Lifesciences Healthcare 9.03 6.53 1.77 1.85
up Ajanta Pharma Healthcare 22.68 1.63 0.00 1.63
down Indoco Remedies Healthcare 20.71 2.50 0.67 1.53
up Vijaya Diagnostic Centre Healthcare 39.76 1.69 0.00 1.42
equal Ipca Laboratories Healthcare 32.57 1.08 0.00 1.08
equal Rainbow Childrens Medicare Healthcare 42.52 0.79 0.00 0.76
equal Orchid Pharma Healthcare 90.09 1.68 0.00 0.70
down Tarsons Products Healthcare 40.35 0.62 0.00 0.60

up down equal Indicates an increase or decrease or no change in holding since last portfolio
new Indicates a new holding since last portfolio

As on 31-Jul-2022

Fund Manager

— Sailesh Raj Bhan since 01-Jan-2013

Education: Mr. Bhan is an MBA (Finance) and CFA.

Experience: Prior to joining Nippon India Mutual Fund, he has worked with Emkay Share & Stock Broker Pvt. Ltd, Shah & Sequeira Invst. Pvt. Ltd, ICFAI- Securities Research Center Analyst - Equity Research.

Funds Managed:


-0.05%

Change from previous, NAV as on 18-Aug-2022

Growth: ₹ 303.9444

IDCW: ₹ 103.7933

Bonus: ₹ 303.9444


Investment Strategy

The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.

Investment Details

Min. Investment (₹) 5,000
Min. Addl Investment (₹) 1,000
Min. SIP Investment (₹) 1,000
Min. No of Cheques 6
Min. Withdrawal (₹) 100
Min. Balance (₹) 1
Lock-in Period Not Applicable
Exit Load 1% for redemption within 30 days

Basic Details

Fund House: Nippon India Mutual Fund
Launch Date: 01-Jan-2013
Return Since Launch: 16.49%
Benchmark: S&P BSE Healthcare TRI
Riskometer: Very High
Type: Open-ended
Assets: ₹ 4,620 Cr (As on 31-Jul-2022)
Expense Ratio: 1.06% (As on 31-Jul-2022)
Risk Grade: --
Return Grade: --
Turnover: 28.00%

Most Recent Dividends

Plan Record Date Dividend (₹ / Unit)  
IDCW25-Feb-20223.5000

 26-Feb-20216.0000
 28-Feb-20203.9843
 05-Mar-20194.4270
 05-Mar-20186.0000
 06-Mar-20176.5000
 04-Mar-20167.0000
 30-Jan-20157.0000
 14-Feb-20144.5000

Registrar & Transfer Agent: KFin Technologies Ltd.

Address: 303, Vamsee Estates, Opp. Big Bazaar, Ameerpet, Hyderabad - 500016

Phone: 040-44857874

Email: [email protected]

Website: www.karvymfs.com

Upcoming Video

Investors' Hangout

Most-asked mutual fund queries answered

DateFri, 19-Aug-2022
Time12:30 PM - 12:40 PM

attending You have reserved a spot